Welcome to our dedicated page for Morgan Stanley SEC filings (Ticker: MS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Morgan Stanley filings document the company’s financial services business, capital structure, governance and material events. The record includes 8-K reports for current events, proxy materials for annual meeting and shareholder voting matters, and securities listings covering common stock, depositary preferred shares and medium-term notes associated with Morgan Stanley Finance LLC.
Filings also disclose governance procedures, registered security classes, NYSE listing information, preferred stock series, debt-security registration matters and formal status changes such as a Form 25 notice for removal of a listed note class from exchange registration.
Morgan Stanley Finance LLC, fully guaranteed by Morgan Stanley, is offering Buffered PLUS notes maturing on January 22, 2031, linked to the S&P 500® Futures Excess Return Index. Each $1,000 note pays no interest and provides 155% leveraged upside if the index finishes above its initial level on the observation date.
If the final index level is at or below the initial level but at or above 80% of it, investors receive only the $1,000 principal. Below the 80% buffer, principal is reduced 1% for each additional 1% decline, with a minimum payment of 20% of principal. The notes are unsecured, subject to Morgan Stanley’s credit risk, not listed on an exchange, and their estimated value on the pricing date is approximately $935.90 per $1,000 note, reflecting embedded costs and an internal funding rate.
Morgan Stanley Finance LLC is offering principal-at-risk structured notes linked to the worst performer of the State Street® Utilities Select Sector SPDR® ETF and the S&P 500® Index. The notes can be automatically called on scheduled determination dates if both references are at or above specified call thresholds, paying step-up early redemption amounts that correspond to about 9.42% per annum, such as $1,094.20 to $1,259.05 per $1,000 security.
If the notes are not called and on the observation date both references are at or above 90% of their initial levels, investors receive $1,282.60 per $1,000. If at least one is below 90% but both are at or above 70%, only the $1,000 principal is repaid. If either falls below 70%, repayment is reduced 1% for every 1% decline in the worst performer, and the payoff can be zero.
The estimated value on the pricing date is approximately $970.50 per security, reflecting issuance, selling, structuring and hedging costs. The notes are unsecured obligations of MSFL, guaranteed by Morgan Stanley, will not be listed on an exchange, and all payments are subject to Morgan Stanley’s credit risk.
Morgan Stanley filed an amended Schedule 13G/A reporting its beneficial ownership in Pliant Therapeutics, Inc. common stock. The firm reports beneficial ownership of 545,228 shares, with shared voting power over 544,224 shares and shared dispositive power over 545,228 shares. This position represents 0.9% of Pliant’s common stock as of the event date of 12/31/2025.
Morgan Stanley notes that, as of this date, it has ceased to be the beneficial owner of more than five percent of this class of securities. The filing also states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Pliant Therapeutics.
Morgan Stanley is offering unsecured fixed rate notes due January 29, 2036, with interest payments tied to its credit risk. Each note has a stated principal amount and issue price of $1,000, pays a fixed 4.500% annual interest rate on a semi-annual basis, and returns principal plus accrued interest at maturity.
The notes are not insured, not listed on any exchange, and secondary trading may be limited, with any market-making by Morgan Stanley & Co. at its discretion. Because issuance, selling, structuring and hedging costs are built into the $1,000 issue price, the estimated value on the pricing date is expected to be approximately $968.40 per note. Proceeds are for general corporate purposes, and affiliated dealers receive sales commissions, creating conflicts of interest highlighted in the risk factors.
Morgan Stanley is offering unsecured fixed rate notes due January 27, 2034. Each note has a stated principal amount and issue price of $1,000 and pays a fixed annual interest rate of 4.350%, with interest paid semi-annually on January 27 and July 27, starting July 27, 2026.
All payments depend on Morgan Stanley’s credit; if the firm fails to meet its obligations, investors could lose some or all of their money. The notes will not be listed on any exchange, and Morgan Stanley & Co. may make a secondary market but is not required to do so. The estimated value on the pricing date is expected to be about $976.50 per note, reflecting issuance, selling, structuring and hedging costs and the firm’s internal funding rate, which makes the investor economics less favorable than a plain-vanilla bond.
Morgan Stanley is offering unsecured fixed rate notes maturing on January 29, 2032. Each note has a stated principal amount and issue price of $1,000 and pays interest at a fixed annual rate of 4.150%, with semi-annual payments each January and July starting on July 29, 2026.
Interest is calculated on a 30/360 basis, and investors receive the stated principal plus accrued interest at maturity, subject to Morgan Stanley’s credit risk. The notes are not insured, will not be listed on any securities exchange, and may have limited or no secondary market. The estimated value on the pricing date is expected to be about $985.20 per note, reflecting issuing, selling, structuring and hedging costs and the issuer’s internal funding rate, which may make the economic terms less favorable than conventional debt.
Morgan Stanley is offering fixed rate senior notes due January 29, 2031. Each note has a stated principal amount and issue price of $1,000 and pays a fixed annual interest rate of 4.00%, with interest paid semi-annually on January 29 and July 29, beginning July 29, 2026, using a 30/360 day-count basis.
At maturity, investors receive $1,000 per note plus accrued and unpaid interest, subject to Morgan Stanley’s credit risk. The notes are unsecured, will not be listed on any securities exchange, and may have limited or no secondary market liquidity. Morgan Stanley estimates the value of each note on the pricing date to be approximately $987.50 or within $57.50 of that estimate, reflecting issuing, selling, structuring and hedging costs and the use of an internal funding rate.
The filing highlights risks including exposure to changes in Morgan Stanley’s credit spreads and ratings, interest rate movements, the lack of listing, potential differences between estimated value and secondary market prices, and conflicts of interest because Morgan Stanley affiliates structure, distribute, value and hedge the notes while also acting as calculation agent.
Morgan Stanley is issuing fixed rate senior notes due January 9, 2031, with an aggregate principal amount of $6,221,000 and a stated principal amount of $1,000 per note. The notes pay 4.000% interest per year, with semi-annual payments each January 9 and July 9, starting July 9, 2026, using a 30/360 day-count convention.
The notes are unsecured and subject to Morgan Stanley’s credit risk, and will not be listed on any securities exchange, so secondary market liquidity may be limited. The issue price is $1,000 per note (or $992.50 in fee-based advisory accounts), while the estimated value on the pricing date is $984.60, reflecting issuing, selling, structuring and hedging costs and the issuer’s internal funding rate. Proceeds will be used for general corporate purposes, and an event of default would accelerate payment of principal plus accrued interest.
Morgan Stanley is offering $3,287,000 of fixed rate notes due January 9, 2034. Each note has a stated principal amount and issue price of $1,000 and pays a fixed interest rate of 4.350% per year, with interest paid semi-annually on January 9 and July 9, starting July 9, 2026, using a 30/360 day-count basis.
The notes are unsecured debt and all payments depend on Morgan Stanley’s credit; a default could result in loss of some or all of the investment. The notes will not be listed on any securities exchange, so secondary market liquidity may be limited and sale prices may be below the issue price. The estimated value on the pricing date is $973.80 per note, below the $1,000 issue price, reflecting internal funding rates and issuance, structuring and hedging costs borne by investors.
Selected dealers generally receive a $12 sales commission per note, while investors in fee-based advisory accounts pay $988 per note with no sales commission. Morgan Stanley expects to use the proceeds for general corporate purposes and its affiliates may hedge and make markets in the notes, which can affect market values.
Morgan Stanley is issuing $344,000 aggregate principal amount of fixed rate notes due January 9, 2032. Each note has a $1,000 stated principal amount and pays a fixed interest rate of 4.150% per annum, with interest paid semi-annually on January 9 and July 9, starting July 9, 2026, using a 30/360 day-count convention.
The issue price is $1,000 per note, but the bank estimates the value on the pricing date at $982.30, reflecting internal funding rates and costs of issuing, selling, structuring and hedging borne by investors. Certain fee-based advisory accounts pay $992.50 per note, and selected dealers receive a $7.50 sales commission per note sold outside those accounts.
The notes are unsecured debt obligations of Morgan Stanley, are not insured by the FDIC, and are not listed on any securities exchange, so secondary market liquidity may be limited and resale prices can be below the issue price. All payments depend on Morgan Stanley’s credit, and changes in its credit ratings, credit spreads or interest rates can reduce the market value of the notes before maturity.